Form 4 for DGX Quest Diagnostics
Accepted 2022-02-28 00:00:00 ET · period of report 2022-02-24 · accession 0001022079-22-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-28 | 2022-02-24 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | A - Grant | $0.00 | +3,328 | 67.7K | +5% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | S - Sale | $126.26 | -2,750 | 64.4K | -4% | -$347.2K |
| D | 2022-02-28 | 2022-02-24 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | A - Grant | $0.00 | +16.2K | 16.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-24 | A | A | 3,328 | $0.00 | 67,733 | D | — | — | (F2) Represents an award of restricted share units. |
| 2 | Common | Common Stock | 2022-02-24 | S | D | 2,750 | $126.26 | 64,405 | D | — | — | |
| 3 | Derivative | Non-Qualifed Stock Option (right to buy) | 2022-02-24 | A | A | 16,155 | $0.00 | 16,155 | D | $127.73 · — to 2032-02-24 | 16,155 Common Stock | (F4) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |